- The FDA has approved Amphastar Pharmaceuticals Inc's (NASDAQ:AMPH) Abbreviated New Drug Application for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe.
- Ganirelix acetate injection is indicated to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
- The FDA determined Amphastar's ganirelix is bioequivalent and therapeutically equivalent to Organon & Co's (NYSE:OGN) Ganirelix Acetate Injection.
- According to IQVIA, the U.S. brand and generic sales for ganirelix acetate injection were approximately $89 million for the 12 months ended December 31, 2021.
- Amphastar plans to launch its Ganirelix Acetate Injection during the second quarter of 2022.
- The Company currently has four ANDAs on file with the FDA targeting products with a market size of approximately $3.9 billion, three biosimilar products in development targeting products with a market size of roughly $13 billion, and eight generic products in development targeting products with a market size of approximately $12 billion.
- Price Action: AMPH shares are down 0.11% at $40.12 during the premarket session on the last check Friday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks